Infiltrative T regulatory cells in enucleated uveal melanomas

Transactions of the American Ophthalmological Society

Volumn 107, Issue , 2009, Pages 223-228

  Lagouros, Evan ^a   Salomao, Diva ^a   Thorland, Erik ^a   Hodge, David O ^a   Vile, Richard ^a   Pulido, Jose S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; ENUCLEATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAOCULAR PRESSURE; LYMPHOCYTIC INFILTRATION; MALE; MEDICAL RECORD REVIEW; MONOSOMY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ULTRASOUND; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; EYE ENUCLEATION; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STAINING AND LABELING; T-LYMPHOCYTES, REGULATORY; UVEAL NEOPLASMS;

EID: 77949396600     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Markovic SN, Erickson LA, Rao RD, et al; Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007;82:364-380.
2. Singh AD, Kivelä T. The collaborative ocular melanoma study. Ophthalmol Clin North Am 2005;18:129-142, ix.
3. Diener-West M, Reynolds SM, Agugliaro DJ, et al; Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005;123:1639-1643.
4. Hawkins BS; Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol 2004;138:936-951.
5. Sieving PA. Fifteen years of work: the COMS outcomes for medium-sized choroidal melanoma. Arch Ophthalmol 2001;119:1067-1068.
6. McLean IW, Saraiva VS, Burnier MN Jr. Pathological and prognostic features of uveal melanomas. Can J Ophthalmol 2004;39:343-350.
7. Niederkorn JY, Wang S. Immunology of intraocular tumors. Ocul Immunol Inflamm 2005;13:105-110.
8. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res 2001;11:255-263.
9. Barnett BG, Rüter J, Kryczek I, et al. Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol 2008;622:255-260.
10. Viguier M, Lemaître F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453.
11. Giatromanolaki A, Bates GJ, Koukourakis MI, et al. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol 2008;110:216-221. Epub 2008 Jun 3.
12. Chen Z, Herman AE, Matos M, Mathis D, Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 2005;202:1387-1397.
13. Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol 2002;2:1.
14. Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in malignant glioma. Anticancer Res 2008;28:1143-1150.
15. Beyer M, Schultze JL. Immunoregulatory T cells: role and potential as a target in malignancy. Curr Oncol Rep 2008;10:130-136.
16. Hori S. Rethinking the molecular definition of regulatory T cells. Eur J Immunol 2008;38:928-930.
17. Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Invest Drugs 2007;8:1002-1008.
18. Sakaguchi S, Wing K, Miyara M. Regulatory T cells - a brief history and perspective. Eur J Immunol 2007;37(suppl 1):S116-123.
19. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075-2081.
20. Vence L, Palucka AK, Fay JW, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2007;104: 20884-20889.
21. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772.
22. Sekulic A, Haluska P Jr, Miller AJ, et al; Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008;83:825-846.
23. Zhang L, Dermawan KT, Jin ML, Xiong SD, Chu YW. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells? Med Hypotheses 2008;71:802-804. Epub 2008 Aug 8.
24. van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007;2007:89017.
25. Curotto de Lafaille MA, Kutchukhidze N, Shen S, Ding Y, Yee H, Lafaille JJ. Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. Immunity 2008;29:114-126.
26. Wu K, Bi Y, Sun K, Xia J, Wang Y, Wang C. Suppression of allergic inflammation by allergen-DNA-modified dendritic cells depends on the induction of Foxp3+ Regulatory T cells. Scand J Immunol 2008;67:140-151.
27. Kido M, Watanabe N, Okazaki T, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology 2008 Jun 25. [Epub ahead of print].
28. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008;223:371-390.